NASDAQ: CPRX
Catalyst Pharmaceuticals is a biopharmaceutical company based in Coral Gables, Florida, dedicated to developing treatments for rare neuromuscular and neurological diseases. Its flagship product, Firdapse, is designed to help patients with Lambert-Eaton Myasthenic Syndrome (LEMS), including a pediatric version named Ruzurgi. The company is also exploring Firdapse's potential for other conditions like MuSK antibody positive myasthenia gravis and spinal muscular atrophy. Catalyst Pharmaceuticals collaborates with industry partners to expand its product offerings, including a partnership for generic medication development.
Tuesday's top analyst upgrades and downgrades included Applied Materials, Bill, Catalyst Pharmaceutical, CVS Health, Elastic, Hawaiian Electric Industries and Walmart.
Wednesday's additional top analyst upgrades and downgrades were on Amazon.com, Beyond Meat, Catalyst Pharmaceuticals, Dick’s Sporting Goods, Macy’s, Medtronic, Twitter, XPeng and more.
The "next" GameStop is certain to be hit fast and hard. Perhaps the WallStreetBets message board on Reddit will target Catalyst Pharmaceuticals or TherapeuticsMD stock.
Douglas A. McIntyre Some small-cap companies will screen as having deep value, but many value stocks are deemed to be "cheap" because they lack any new catalysts and opportunities.
Jon C. Ogg Robinhood has become the dominant discount brokerage platform over the last year. It had 4.3 million average revenue trades in June, which is a critical metric in the industry. This is higher…
Some companies Robinhood traders find most attractive are very risky bets. A hit to the financials of one of these companies or a piece of bad news could easily trigger an extreme…
A new SunTrust Robinson Humphrey research report focuses in on biotech companies that have upcoming clinical data that could prove to be huge.
Lee Jackson The broad markets are inching forward on Wednesday after hitting new highs in what has been known as the Trump rally. Although the SPDR S&P Biotech ETF (NYSEMKT: XBI) is up about…
The the top analyst upgrades, downgrades and initiations seen on Wednesday morning include Broadcom, Flex, Genworth Financial, Micron Technology, Salesforce.com, UBS and Wal-Mart.
Apple, Twitter and other companies punished shareholders last week, and analysts expect more earnings disappointments going forward.
Catalyst Pharmaceuticals saw its shares get halved just Tuesday morning alone, following a business update regarding its Lambert-Eaton myasthenic syndrome treatment.
Chris Lange Rite Aid has announced that it will acquire EnvisionRx for $2 billion from the private equity firm TPG Capital.
ThinkstockCatalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) announced positive topline results from its Phase 3 clinical trial of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS. In the study, Firdapse…
Chris Lange August 27, 2013: U.S. markets opened lower Tuesday morning with worries over possible U.S. actions in Syria weighing prices down all day. The S&P Case-Shiller house price index was strong again in…
thinkstockHere are today’s five biggest gaining stocks at closing: Superconductor Technologies Inc. (NASDAQ: SCON) is up 134.9% at $5.45. MEMSIC Inc. (NASDAQ: MEMS) is up 50.8% at $4.07. Ceasars Entertainment Corp. (NASDAQ:…
Catalyst Pharmaceuticals is a biopharmaceutical company based in Coral Gables, Florida, dedicated to developing treatments for rare neuromuscular and neurological diseases.
